Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902 Meeting Abstract
| Authors: | Luger, S.; Wang, V. X.; Paietta, E.; Ketterling, R. P.; Rybka, W.; Lazarus, H. M.; Litzow, M. R.; Rowe, J. M.; Larson, R. A.; Appelbaum, F. R.; Tallman, M. S. |
| Abstract Title: | Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902 |
| Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 126 |
| Issue: | 23 |
| Meeting Dates: | 2015 Dec 5-8 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-03 |
| Language: | English |
| ACCESSION: | WOS:000368019004108 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V126.23.1308.1308 |
| Notes: | Meeting Abstract: 1308 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |
